Suppr超能文献

用激酶抑制剂靶向治疗癌症。

Targeting cancer with kinase inhibitors.

作者信息

Gross Stefan, Rahal Rami, Stransky Nicolas, Lengauer Christoph, Hoeflich Klaus P

出版信息

J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.

Abstract

Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.

摘要

激酶抑制剂在癌症和其他疾病的治疗中发挥着越来越重要的作用。目前,已有超过25种靶向激酶的肿瘤药物获批,还有许多其他疗法正处于临床评估的不同阶段。在本综述中,我们深入分析了癌症中激酶的激活机制,突出了药物研发的近期成果,并展示了选择性激酶抑制剂的临床影响。我们还描述了在设计新一代抑制剂以规避靶向耐药机制方面取得的重大进展,以及激酶抑制剂联合应用的临床策略。最后,发现新型激酶靶点的前景广阔,我们将癌症免疫疗法作为研究激酶生物学的一个新的、有前景的研究领域进行了探讨。

相似文献

1
Targeting cancer with kinase inhibitors.
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
2
The Stress Kinase p38α as a Target for Cancer Therapy.
Cancer Res. 2015 Oct 1;75(19):3997-4002. doi: 10.1158/0008-5472.CAN-15-0173. Epub 2015 Sep 16.
3
[The HER3/ERBB3 receptor: the dark side of the ERBB planet].
Med Sci (Paris). 2015 May;31(5):465-8. doi: 10.1051/medsci/20153105002. Epub 2015 Jun 9.
4
Targeting cancer with small molecule kinase inhibitors.
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
5
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.
6
Enzastaurin.
Expert Opin Investig Drugs. 2008 Jun;17(6):939-44. doi: 10.1517/13543784.17.6.939.
7
Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.
Expert Opin Ther Targets. 2002 Dec;6(6):659-78. doi: 10.1517/14728222.6.6.659.
8
Emerging Targeted Therapy for Tumors with Fusion Proteins.
Clin Cancer Res. 2018 Dec 1;24(23):5807-5814. doi: 10.1158/1078-0432.CCR-18-1156. Epub 2018 Jul 9.
9
Protein kinases: From targets to anti-cancer drugs.
Ann Pharm Fr. 2010 Jul;68(4):254-9. doi: 10.1016/j.pharma.2010.03.007. Epub 2010 May 27.
10
BRAF inhibitors in cancer therapy.
Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8.

引用本文的文献

1
The Role of Protein Kinases in the Suppressive Phenotype of Myeloid-Derived Suppressor Cells.
Int J Mol Sci. 2025 Jul 19;26(14):6936. doi: 10.3390/ijms26146936.
4
Exploring anticancer activity of baicalin, naringenin, and noscapine via binding and inhibition of sphingosine kinase 1.
3 Biotech. 2025 Jun;15(6):195. doi: 10.1007/s13205-025-04356-9. Epub 2025 May 29.
6
Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis.
Proc Natl Acad Sci U S A. 2025 Feb 18;122(7):e2415244122. doi: 10.1073/pnas.2415244122. Epub 2025 Feb 12.
7
MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity.
Cell Rep. 2025 Jan 28;44(1):115120. doi: 10.1016/j.celrep.2024.115120. Epub 2024 Dec 24.
9
Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.
Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2402741121. doi: 10.1073/pnas.2402741121. Epub 2024 Sep 25.
10
Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication.
J Virol. 2024 Oct 22;98(10):e0112924. doi: 10.1128/jvi.01129-24. Epub 2024 Sep 17.

本文引用的文献

2
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
3
Immuno-oncology combinations: a review of clinical experience and future prospects.
Clin Cancer Res. 2014 Dec 15;20(24):6258-68. doi: 10.1158/1078-0432.CCR-14-1457. Epub 2014 Oct 23.
5
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.
7
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
8
Ipilimumab in the treatment of advanced melanoma - a clinical update.
Expert Opin Biol Ther. 2014 Nov;14(11):1709-18. doi: 10.1517/14712598.2014.963053. Epub 2014 Sep 24.
9
The landscape of kinase fusions in cancer.
Nat Commun. 2014 Sep 10;5:4846. doi: 10.1038/ncomms5846.
10
Oncogene withdrawal engages the immune system to induce sustained cancer regression.
J Immunother Cancer. 2014 Jul 15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验